Although these drugs have appreciably improved the outcomes of patients with imatinib-resistant CML, they are still ineffective against the BCR/ABL gatekeeper mutation T315I [5]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.